SIRONA BIOCHEM CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.065 CAD | -7.14% |
|
+8.33% | -45.83% |
| Apr. 08 | Sirona Biochem Provides Update on Anti-Aging Product | MT |
| Apr. 04 | Sirona Biochem Corp. announced that it has received CAD 0.1325 million in funding | CI |
Valuation
| Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 17.04 | 98.44 | 56.58 | 46.61 | 32.73 | 21.44 |
| Enterprise Value (EV) 1 | 19.21 | 96.26 | 56.28 | 46.68 | 32.77 | 23.05 |
| P/E ratio | -12.8 x | -19.7 x | -13.7 x | -19.9 x | -8.81 x | -8.43 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 13.3 x | 725 x | 535 x | 174 x | 48.7 x | 616 x |
| EV / Revenue | 15 x | 709 x | 532 x | 174 x | 48.8 x | 663 x |
| EV / EBITDA | -28.5 x | - | -14.1 x | -22 x | -9.7 x | -10 x |
| EV / FCF | -227 x | -54.8 x | -86.5 x | -37.8 x | -34.8 x | -57.6 x |
| FCF Yield | -0.44% | -1.83% | -1.16% | -2.64% | -2.88% | -1.74% |
| Price to Book | -7.53 x | 45.5 x | 1,196 x | -488 x | 153 x | -8.58 x |
| Nbr of stocks (in thousands) | 179,326 | 221,222 | 226,309 | 233,045 | 251,732 | 252,224 |
| Reference price 2 | 0.0950 | 0.4450 | 0.2500 | 0.2000 | 0.1300 | 0.0850 |
| Announcement Date | 3/4/19 | 3/2/20 | 3/3/21 | 2/28/22 | 2/28/23 | 2/28/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.279 | 0.1357 | 0.1057 | 0.268 | 0.6719 | 0.0348 |
| EBITDA 1 | -0.6728 | - | -3.985 | -2.125 | -3.38 | -2.303 |
| EBIT 1 | -0.8563 | -4.199 | -3.995 | -2.134 | -3.39 | -2.313 |
| Operating Margin | -66.96% | -3,093.19% | -3,779.24% | -796.37% | -504.45% | -6,649.66% |
| Earnings before Tax (EBT) 1 | -1.153 | -4.556 | -4.141 | -2.312 | -3.552 | -2.544 |
| Net income 1 | -1.273 | -4.55 | -4.134 | -2.306 | -3.558 | -2.543 |
| Net margin | -99.57% | -3,351.61% | -3,910.4% | -860.5% | -529.5% | -7,312.43% |
| EPS 2 | -0.007412 | -0.0226 | -0.0183 | -0.0101 | -0.0148 | -0.0101 |
| Free Cash Flow 1 | -0.0846 | -1.758 | -0.6504 | -1.234 | -0.9425 | -0.4001 |
| FCF margin | -6.61% | -1,295.08% | -615.28% | -460.35% | -140.27% | -1,150.34% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/4/19 | 3/2/20 | 3/3/21 | 2/28/22 | 2/28/23 | 2/28/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 2.17 | - | - | 0.07 | 0.05 | 1.61 |
| Net Cash position 1 | - | 2.19 | 0.29 | - | - | - |
| Leverage (Debt/EBITDA) | -3.226 x | - | - | -0.0338 x | -0.0142 x | -0.6994 x |
| Free Cash Flow 1 | -0.08 | -1.76 | -0.65 | -1.23 | -0.94 | -0.4 |
| ROE (net income / shareholders' equity) | 59.2% | 12,739% | -370% | 9,296% | -6,056% | 221% |
| ROA (Net income/ Total Assets) | -52.9% | -104% | -78.1% | -77.9% | -164% | -124% |
| Assets 1 | 2.405 | 4.358 | 5.293 | 2.96 | 2.165 | 2.043 |
| Book Value Per Share 2 | -0.0100 | 0.0100 | 0 | -0 | 0 | -0.0100 |
| Cash Flow per Share 2 | 0 | 0.0200 | 0.0100 | 0 | 0 | 0 |
| Capex | - | - | 0.05 | - | - | - |
| Capex / Sales | - | - | 44.43% | - | - | - |
| Announcement Date | 3/4/19 | 3/2/20 | 3/3/21 | 2/28/22 | 2/28/23 | 2/28/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -45.83% | 12.18M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SBM Stock
- Financials Sirona Biochem Corp.
